Cargando…
The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys
The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused disruption in all aspects of daily life, including the management and treatment of rare inherited metabolic disorders (IMDs). To perform a preliminary assessment of the incidence of COVID-19 in IMD patients and the impact of the cor...
Autores principales: | Lampe, C., Dionisi-Vici, C., Bellettato, C. M., Paneghetti, L., van Lingen, C., Bond, S., Brown, C., Finglas, A., Francisco, R., Sestini, S., Heard, J. M., Scarpa, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711270/ https://www.ncbi.nlm.nih.gov/pubmed/33272301 http://dx.doi.org/10.1186/s13023-020-01619-x |
Ejemplares similares
-
Social and medical needs of rare metabolic patients: results from a MetabERN survey
por: Sestini, Sylvia, et al.
Publicado: (2021) -
Research activity and capability in the European reference network MetabERN
por: Heard, Jean-Michel, et al.
Publicado: (2019) -
One year of COVID-19: infection rates and symptoms in patients with inherited metabolic diseases followed by MetabERN
por: Paneghetti, Laura, et al.
Publicado: (2022) -
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network
por: Heard, Jean-Michel, et al.
Publicado: (2020) -
Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
por: Stepien, Karolina M., et al.
Publicado: (2021)